GSK

GSK

Market cap $104B

GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.

GSK plc (NYSE:GSK) on Friday announced a pivotal update regarding its Phase 3 clinical program for camlipixant, revealing a strategic decision to halt further development for refractory chronic cough (RCC).

Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach without straining the profit and loss account.

GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.

GSK on ‌Friday said it had decided not to develop ​its experimental drug ​to treat refractory chronic ⁠cough further after it ​did not meet ​one of its main goals in a late-stage trial.

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.

UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.

GSK said on Monday its cancer drug Jemperli met the ​primary goal of a mid-stage trial, with ‌a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of ​locally advanced rectal cancer.

British drugmaker ​GSK's experimental ‌drug for treating ​patients ​with advanced or ⁠relapsed ​small-cell ​lung cancer showed positive ​results ​in a late-stage ‌trial ⁠on Friday.